Insiders Buy Big, Dump Bigger
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Two contrasting insider signals dominated filings this week — a massive bet on a biotech and a wave of selling at a chip equipment giant.
SMMT saw its CEO and Chairman Robert Duggan file a $50M purchase on June 12. He bought 3.81 million shares at $13.12 each. That same week, President/CEO Maky Zanganeh filed a separate $1.46M buy. The CFO also added shares. Three executives buying at the same time is a strong vote of confidence from Summit Therapeutics' top team.
The picture at AMAT was the opposite. CEO Gary Dickerson filed sales totalling over $63M on June 17. The trades happened on June 15–16 at prices around $590–$597 per share. The company's CTO, Omkaram Nalamasu, filed another $9M in sales on the same dates. The board chairman sold nearly $5.6M more. Applied Materials insiders collectively offloaded well over $70M in just two days.
Also notable: DVA CEO Javier Rodriguez filed an $8.2M sale on June 17. He sold 39,407 shares in DaVita at roughly $209 each.
The SMMT cluster of buys stands out. When a CEO puts $50M of personal money into shares, that is rarely routine. The AMAT selling, by contrast, looks coordinated — multiple executives filing on the same day at similar prices.
Stocks in this article
How this article was generated
- Generated
- 21 Jun 2026, 08:13
- Prompt version
- v1.0
- Data sources
- Institutional positioning
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.